# Combination CAR-T Cell Therapy Targeting Hematological Malignancies

> **NCT03125577** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 100 (estimated)

## Conditions studied

- B-cell Malignancies

## Interventions

- **BIOLOGICAL:** 4SCAR19 and 4SCAR22
- **BIOLOGICAL:** 4SCAR19 and 4SCAR38
- **BIOLOGICAL:** 4SCAR19 and 4SCAR20
- **BIOLOGICAL:** 4SCAR19 and 4SCAR123
- **BIOLOGICAL:** 4SCAR19 and 4SCAR70
- **BIOLOGICAL:** 4SCAR19 and 4SCAR30

## Key facts

- **NCT ID:** NCT03125577
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125577, "Combination CAR-T Cell Therapy Targeting Hematological Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03125577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*